OTCMKTS:BIOVF Q2 EPS Forecast Decreased by HC Wainwright

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) – Stock analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for Swedish Orphan Biovitrum in a report released on Friday, May 22nd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of $0.38 per share for the quarter, down from their prior estimate of $0.39. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $2.22 per share. HC Wainwright also issued estimates for Swedish Orphan Biovitrum’s Q4 2026 earnings at $0.77 EPS, FY2026 earnings at $2.22 EPS, Q1 2027 earnings at $0.68 EPS, Q3 2027 earnings at $1.07 EPS, Q4 2027 earnings at $1.06 EPS and FY2027 earnings at $3.44 EPS.

BIOVF has been the subject of a number of other reports. Zacks Research raised Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Danske cut Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Finally, Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Swedish Orphan Biovitrum has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

Shares of OTCMKTS BIOVF opened at $47.48 on Monday. Swedish Orphan Biovitrum has a twelve month low of $27.06 and a twelve month high of $47.48. The company has a current ratio of 0.90, a quick ratio of 0.59 and a debt-to-equity ratio of 0.14. The stock has a fifty day simple moving average of $42.64 and a 200-day simple moving average of $38.53. The stock has a market capitalization of $16.90 billion, a PE ratio of 158.25 and a beta of 0.34.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. Swedish Orphan Biovitrum had a return on equity of 17.23% and a net margin of 3.37%.The business had revenue of $755.76 million during the quarter, compared to analysts’ expectations of $749.76 million.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.